Multiple Sclerosis, Relapsing-Remitting
"Multiple Sclerosis, Relapsing-Remitting" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
|Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Relapsing Remitting
- Remitting-Relapsing Multiple Sclerosis
- Multiple Sclerosis, Remitting-Relapsing
- Remitting Relapsing Multiple Sclerosis
- Relapsing-Remitting Multiple Sclerosis
- Relapsing Remitting Multiple Sclerosis
Below are MeSH descriptors whose meaning is more general than "Multiple Sclerosis, Relapsing-Remitting".
Below are MeSH descriptors whose meaning is more specific than "Multiple Sclerosis, Relapsing-Remitting".
This graph shows the total number of publications written about "Multiple Sclerosis, Relapsing-Remitting" by people in this website by year, and whether "Multiple Sclerosis, Relapsing-Remitting" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Multiple Sclerosis, Relapsing-Remitting" by people in Profiles.
Biomarker panel increases accuracy for identification of an MS relapse beyond sNfL. Mult Scler Relat Disord. 2022 Jul; 63:103922.
Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial. Ann Clin Transl Neurol. 2021 03; 8(3):711-715.
Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 1: From the National Multiple Sclerosis Society Case Conference Proceedings. Neurol Neuroimmunol Neuroinflamm. 2021 01; 8(1).
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J Neurol. 2020 Nov; 267(11):3343-3353.
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol. 2017 Dec; 264(12):2351-2374.
IFN-ß treatment requires B cells for efficacy in neuroautoimmunity. J Immunol. 2015 Mar 01; 194(5):2110-6.
Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2014 Jun 15; 341(1-2):22-7.
Interleukin 17F level and interferon ß response in patients with multiple sclerosis. JAMA Neurol. 2013 Aug; 70(8):1017-21.
Repeatability of the timed 25-foot walk test for individuals with multiple sclerosis. Clin Rehabil. 2013 Aug; 27(8):719-23.
Janus-like effects of type I interferon in autoimmune diseases. Immunol Rev. 2012 Jul; 248(1):23-35.